ABSTRACT
This is a patient case report of an adult onset progressive giant T wave inversion without valvular or coronary artery disease, which was confirmed to be showing apical hypertrophic cardiomyopathy (AHCM) by cardiac MRI. AHCM is a relatively rare form of hypertrophic cardiomyopathy (HCM) accounting for only 3% of all cases of HCM. Relatively little is known regarding prognosis and optimal management of this condition compared to HCM. We present a case report of AHCM and a review of the literature available regarding this condition.
Subject(s)
Cardiomyopathy, Hypertrophic/diagnosis , Cardiomyopathy, Hypertrophic/epidemiology , Electrocardiography , Magnetic Resonance Imaging , Humans , Male , Middle Aged , Risk FactorsABSTRACT
The present study assessed the magnitude of inhibition of platelet aggregation induced by adenosine diphosphate and thrombin receptor activating peptide achieved with unfractionated heparin, the direct thrombin inhibitor bivalirudin, and the glycoprotein IIb/IIIa inhibitor eptifibatide in patients who underwent percutaneous coronary intervention and and were treated with concomitant aspirin and clopidogrel.
Subject(s)
Angioplasty, Balloon, Coronary , Heparin/therapeutic use , Hirudins/pharmacokinetics , Myocardial Ischemia/therapy , Peptide Fragments/pharmacokinetics , Peptides/pharmacokinetics , Platelet Aggregation/drug effects , Ticlopidine/analogs & derivatives , Anticoagulants/pharmacokinetics , Anticoagulants/therapeutic use , Clopidogrel , Drug Therapy, Combination , Eptifibatide , Female , Follow-Up Studies , Humans , Male , Middle Aged , Myocardial Ischemia/blood , Peptide Fragments/therapeutic use , Peptides/therapeutic use , Platelet Aggregation Inhibitors/pharmacokinetics , Platelet Aggregation Inhibitors/therapeutic use , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Preoperative Care/methods , Recombinant Proteins/pharmacokinetics , Recombinant Proteins/therapeutic use , Ticlopidine/pharmacokinetics , Ticlopidine/therapeutic use , Treatment OutcomeABSTRACT
We performed a comparative analysis of platelet aggregation inhibition achieved with the glycoprotein IIb/IIIa inhibitors eptifibatide and tirofiban HCl in patients who underwent percutaneous coronary intervention and used light transmission aggregometric assays with D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone as an anticoagulant and 20 micromol of adenosine diphosphate as an agonist. Taking into account the differences in clinical efficacy of these 2 drugs in large trials investigating percutaneous coronary intervention, we hypothesized that the variable clinical effects might be related to variability in the magnitude and consistency of platelet aggregation inhibition achieved with dosing regimens of these glycoprotein IIb/IIIa inhibitors.
